Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.
Hultgren
C
C
Divisions of Clinical Virology, Basic Oral Sciences, Karolinska Institutet at Huddinge University Hospital, Huddinge, Sweden.
Weiland
O
O
Milich
D R
DR
Sällberg
M
M
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood / Q000187:drug effects; D004359:Drug Therapy, Combination; D000077595:Famciclovir; D006513:Hepatitis B e Antigens / Q000097:blood / Q000187:drug effects*; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000254:growth & development; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome; D014779:Virus Replication
D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D019259:Lamivudine; D015075:2-Aminopurine; D000077595:Famciclovir